Document is current
Any future updates will be listed below
-
Authors
El, Kimberley https://orcid.org/0000-0002-5550-1684
Douros, Jonathan D.
Willard, Francis S. https://orcid.org/0000-0002-4260-2451
Novikoff, Aaron https://orcid.org/0000-0002-4838-001X
Sargsyan, Ashot https://orcid.org/0000-0003-1662-7548
Perez-Tilve, Diego https://orcid.org/0000-0002-0351-4133
Wainscott, David B.
Yang, Bin https://orcid.org/0000-0003-1180-6184
Chen, Alex https://orcid.org/0000-0001-5666-391X
Wothe, Donald
Coupland, Callum https://orcid.org/0000-0001-8921-3616
Tschöp, Mattias H. https://orcid.org/0000-0002-4744-371X
Finan, Brian https://orcid.org/0000-0002-6467-0447
D’Alessio, David A. https://orcid.org/0000-0003-4155-4870
Sloop, Kyle W. https://orcid.org/0000-0001-6748-9929
Müller, Timo D. https://orcid.org/0000-0002-0624-9339
Campbell, Jonathan E. https://orcid.org/0000-0003-4358-6331
- License Information
-
More Information
Article History
Received: 21 November 2022
Accepted: 21 April 2023
First Online: 5 June 2023
Competing interests
: The Campbell group receives funding for basic science from Novo Nordisk and Eli Lilly. The Müller group receives funding for basic science from Novo Nordisk. F.S.W., D.B.W. and K.W.S. are employees of Eli Lilly. J.D.D., B.Y. and B.F. are employees of Novo Nordisk. D.A.D. has served as a consultant or speaker within the past 12 months for Eli Lilly and Structure Therapeutics. J.E.C. has served as a consultant or speaker within the past 12 months for Structure Therapeutics. The remaining authors declare no competing interests or conflict of interest.
